NCT04690348
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease
Exclusions: Patients with leptomeningeal carcinomatosis or greater than 5 additional active or untreated CNS lesions for a total of greater than 6 active lesions
https://ClinicalTrials.gov/show/NCT04690348